Lilly gains after FDA approves weight-loss pill, sizing down investor doubts

Eli Lilly received FDA approval for its weight-loss pill Foundayo and shares jumped nearly 6% on the news. The approval is a significant milestone that strengthens Lilly's position in the lucrative obesity market and could meaningfully boost the company's growth prospects in the category.

Analysis

Eli Lilly received FDA approval for its weight-loss pill Foundayo and shares jumped nearly 6% on the news. The approval is a significant milestone that strengthens Lilly's position in the lucrative obesity market and could meaningfully boost the company's growth prospects in the category.